The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Should we screen for and treat myeloma precursor conditions?
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the potential benefits of screening for monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), referencing the iStop MM trial (NCT03327597). The trial indicates that early treatment in these precursor stages can lead to less severe myeloma. However, the lack of long-term follow-up leaves the impact on survival and the feasibility of population-wide screening unclear. Thus, Dr Schjesvold concludes that screening for these precursor conditions is not currently recommended but may become important in the future. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria for lectures and educational material: Skylite DX, Schain, Novartis, Janssen-Cilag, Takeda, Pfizer, Oncopeptides, Amgen, Sanofi, Bristol Myers Squibb, Daiichi Sankyo, Celgene, GlaxoSmithKline, Abbvie
Consultancy: Janssen-Cilag, Takeda, Oncopeptides, Sanofi, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Abbvie
Research Funding: Janssen-Cilag, Oncopeptides, Sanofi, Targovax, Celgene, GlaxoSmithKline
